---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-307300"
form_type: "8-K"
ticker: "AGIO"
cik: "0001439222"
company_name: "AGIOS PHARMACEUTICALS, INC."
filed_at: "2022-12-16T23:59:59+00:00"
generated_at: "2026-06-21T03:15:34.382950+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Agios adopts performance-based cash bonus for CMO tied to ENERGIZE trial milestone

## Summary
- Dr. Sarah Gheuens, CMO and Head of R&D, eligible for up to 1.25x her 2022 target bonus ($309,375) if ENERGIZE trial milestone achieved by April 2024.
- If milestone achieved before April 2024, bonus increases to 1.2x the baseline amount, totaling $371,250.
- Bonus payment contingent on Dr. Gheuens remaining employed at time of milestone achievement.
- CEO, CFO, and Chief Commercial Officer are not eligible for this bonus plan.

## SEC filing metadata
- accession: 0001193125-22-307300
- form_type: 8-K
- ticker: AGIO
- cik: 0001439222
- company_name: AGIOS PHARMACEUTICALS, INC.
- filed_at: 2022-12-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439222/000119312522307300/0001193125-22-307300-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439222/000119312522307300/d428911d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-307300
- JSON: https://secwatch.observer/filing/0001193125-22-307300.json
- Plain text: https://secwatch.observer/filing/0001193125-22-307300.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.